ArticleJournal of tropical medicine2026
Human Metapneumovirus Nucleocapsid Inhibitors Discovery for Targeting Viral Replication and Genome Encapsidation: An In Silico Approach.
Article in Journal of tropical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Human Metapneumovirus Nucleocapsid Inhibitors Discovery for Targeting Viral Replication and Genome Encapsidation: An In Silico Approach.Journal of tropical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human metapneumovirus (HMPV) is a major respiratory pathogen, and its infection is more severe in infants, the elderly, and immunocompromised individuals. Despite its significance, no antiviral drugs are approved to combat HMPV infection. Therefore, it is important to develop drugs that target the nucleocapsid protein, which is crucial for viral replication and genome encapsidation. In this study, computational drug discovery was used to identify new potential molecules targeting the HMPV nucleocapsid protein. In the first step, the virtual screening method was applied to a compound library, and the top three compounds were selected for further redocking using AutoDock Vina. Finally, the chosen compounds were subjected to molecular dynamics simulations, and the stability of the complex and its conformational stability were evaluated using root mean square deviation, root mean square fluctuation, principal component analysis, and binding free energy landscape analysis. Among the chosen compounds, 24,330,502, 24,292,974, and 17,515,455 showed high binding affinity, stability, and conformational stability, and their results were better than those of the reference compound, Gamma-Fagarine, and they retained the ligands in the binding pocket with high stability. Therefore, the results of the present study reveal that the selected compounds, namely, 24,330,502, 24,292,974, and 17,515,455, have the potential to inhibit the HMPV nucleocapsid protein and are thus important for the treatment of HMPV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.